AI and blood tests aim to replace risky liver biopsies
NCT ID NCT06819917
Summary
This study aims to find better, non-invasive ways to diagnose liver scarring (fibrosis) in people with fatty liver disease. Researchers will collect blood samples from 575 participants and compare new blood tests and AI-powered ultrasound to the current gold standard, a liver biopsy. The goal is to develop safer, more accessible tools to accurately measure how much scarring is present in the liver.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hvidovre Hospital
RECRUITINGCopenhagen, Denmark
Contact Email: •••••@•••••
-
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
RECRUITINGMainz, Germany
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.